34809709|t|CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice.
34809709|a|BACKGROUND: Neurocognitive impairment is present in 50% of HIV-infected individuals and is often associated with Alzheimer's Disease (AD)-like brain pathologies, including increased amyloid-beta (Abeta) and Tau hyperphosphorylation. Here, we aimed to determine whether HIV-1 infection causes AD-like pathologies in an HIV/AIDS humanized mouse model, and whether the CCR5 antagonist maraviroc alters HIV-induced pathologies. METHODS: NOD/scid-IL-2Rgammacnull mice engrafted with human blood leukocytes were infected with HIV-1, left untreated or treated with maraviroc (120 mg/kg twice/day). Human cells in animal's blood were quantified weekly by flow cytometry. Animals were sacrificed at week-3 post-infection; blood and tissues viral loads were quantified using p24 antigen ELISA, RNAscope, and qPCR. Human (HLA-DR+) cells, Abeta-42, phospho-Tau, neuronal markers (MAP 2, NeuN, neurofilament-L), gamma-secretase activating protein (GSAP), and blood-brain barrier (BBB) tight junction (TJ) proteins expression and transcription were quantified in brain tissues by immunohistochemistry, immunofluorescence, immunoblotting, and qPCR. Plasma Abeta-42, Abeta-42 cellular uptake, release and transendothelial transport were quantified by ELISA. RESULTS: HIV-1 significantly decreased human (h)CD4+ T-cells and hCD4/hCD8 ratios; decreased the expression of BBB TJ proteins claudin-5, ZO-1, ZO-2; and increased HLA-DR+ cells in brain tissues. Significantly, HIV-infected animals showed increased plasma and brain Abeta-42 and phospho-Tau (threonine181, threonine231, serine396, serine199), associated with transcriptional upregulation of GSAP, an enzyme that catalyzes Abeta formation, and loss of MAP 2, NeuN, and neurofilament-L. Maraviroc treatment significantly reduced blood and brain viral loads, prevented HIV-induced loss of neuronal markers and TJ proteins; decreased HLA-DR+ cells infiltration in brain tissues, significantly reduced HIV-induced increase in Abeta-42, GSAP, and phospho-Tau. Maraviroc also reduced Abeta retention and increased Abeta release in human macrophages; decreased the receptor for advanced glycation end products (RAGE) and increased low-density lipoprotein receptor-related protein-1 (LRP1) expression in human brain endothelial cells. Maraviroc induced Abeta transendothelial transport, which was blocked by LRP1 antagonist but not RAGE antagonist. CONCLUSIONS: Maraviroc significantly reduced HIV-induced amyloidogenesis, GSAP, phospho-Tau, neurodegeneration, BBB alterations, and leukocytes infiltration into the CNS. Maraviroc increased cellular Abeta efflux and transendothelial Abeta transport via LRP1 pathways. Thus, therapeutically targeting CCR5 could reduce viremia, preserve the BBB and neurons, increased brain Abeta efflux, and reduce AD-like neuropathologies.
34809709	0	4	CCR5	Gene	12774
34809709	24	27	HIV	Species	11676
34809709	36	51	amyloidogenesis	Disease	
34809709	53	56	tau	Gene	4137
34809709	68	85	neurodegeneration	Disease	MESH:D019636
34809709	126	138	HIV-infected	Disease	MESH:D015658
34809709	150	154	mice	Species	10090
34809709	168	193	Neurocognitive impairment	Disease	MESH:D019965
34809709	215	227	HIV-infected	Disease	MESH:D015658
34809709	269	288	Alzheimer's Disease	Disease	MESH:D000544
34809709	290	292	AD	Disease	MESH:D000544
34809709	299	316	brain pathologies	Disease	MESH:D005598
34809709	352	357	Abeta	Gene	11820
34809709	363	366	Tau	Gene	4137
34809709	425	440	HIV-1 infection	Disease	MESH:D015658
34809709	448	450	AD	Disease	MESH:D000544
34809709	474	482	HIV/AIDS	Disease	MESH:D015658
34809709	493	498	mouse	Species	10090
34809709	522	526	CCR5	Gene	12774
34809709	538	547	maraviroc	Chemical	MESH:D000077592
34809709	555	558	HIV	Species	11676
34809709	614	618	mice	Species	10090
34809709	634	639	human	Species	9606
34809709	662	670	infected	Disease	MESH:D007239
34809709	676	681	HIV-1	Species	11676
34809709	714	723	maraviroc	Chemical	MESH:D000077592
34809709	747	752	Human	Species	9606
34809709	858	867	infection	Disease	MESH:D007239
34809709	960	965	Human	Species	9606
34809709	983	991	Abeta-42	Gene	351
34809709	1001	1004	Tau	Gene	4137
34809709	1024	1029	MAP 2	Gene	4133
34809709	1031	1035	NeuN	Gene	146713
34809709	1055	1089	gamma-secretase activating protein	Gene	212167
34809709	1091	1095	GSAP	Gene	212167
34809709	1407	1412	HIV-1	Species	11676
34809709	1437	1442	human	Species	9606
34809709	1446	1449	CD4	Gene	920
34809709	1525	1534	claudin-5	Gene	7122
34809709	1536	1540	ZO-1	Gene	7082
34809709	1542	1546	ZO-2	Gene	9414
34809709	1609	1621	HIV-infected	Disease	MESH:D015658
34809709	1664	1672	Abeta-42	Gene	351
34809709	1685	1688	Tau	Gene	4137
34809709	1789	1793	GSAP	Gene	212167
34809709	1820	1825	Abeta	Gene	351
34809709	1849	1854	MAP 2	Gene	4133
34809709	1856	1860	NeuN	Gene	146713
34809709	1883	1892	Maraviroc	Chemical	MESH:D000077592
34809709	1964	1967	HIV	Species	11676
34809709	2095	2098	HIV	Species	11676
34809709	2119	2127	Abeta-42	Gene	351
34809709	2129	2133	GSAP	Gene	54103
34809709	2147	2150	Tau	Gene	4137
34809709	2152	2161	Maraviroc	Chemical	MESH:D000077592
34809709	2175	2180	Abeta	Gene	351
34809709	2205	2210	Abeta	Gene	351
34809709	2222	2227	human	Species	9606
34809709	2255	2299	receptor for advanced glycation end products	Gene	177
34809709	2301	2305	RAGE	Gene	177
34809709	2321	2371	low-density lipoprotein receptor-related protein-1	Gene	4035
34809709	2373	2377	LRP1	Gene	4035
34809709	2393	2398	human	Species	9606
34809709	2424	2433	Maraviroc	Chemical	MESH:D000077592
34809709	2442	2447	Abeta	Gene	351
34809709	2497	2501	LRP1	Gene	4035
34809709	2521	2525	RAGE	Gene	177
34809709	2551	2560	Maraviroc	Chemical	MESH:D000077592
34809709	2583	2586	HIV	Species	11676
34809709	2595	2610	amyloidogenesis	Disease	
34809709	2612	2616	GSAP	Gene	54103
34809709	2626	2629	Tau	Gene	4137
34809709	2631	2648	neurodegeneration	Disease	MESH:D019636
34809709	2709	2718	Maraviroc	Chemical	MESH:D000077592
34809709	2738	2743	Abeta	Gene	351
34809709	2772	2777	Abeta	Gene	351
34809709	2792	2796	LRP1	Gene	4035
34809709	2839	2843	CCR5	Gene	1234
34809709	2857	2864	viremia	Disease	MESH:D014766
34809709	2912	2917	Abeta	Gene	351
34809709	2937	2939	AD	Disease	MESH:D000544
34809709	2945	2961	neuropathologies	Disease	MESH:D009422
34809709	Positive_Correlation	MESH:D000544	11820
34809709	Association	MESH:D015658	146713
34809709	Association	MESH:D014766	4035
34809709	Association	1234	177
34809709	Association	MESH:D015658	4133
34809709	Association	MESH:D015658	12774
34809709	Association	MESH:D009422	1234
34809709	Association	MESH:D019965	4137
34809709	Association	MESH:D015658	212167
34809709	Association	212167	4137
34809709	Positive_Correlation	MESH:D015658	4137
34809709	Association	1234	4035
34809709	Positive_Correlation	212167	351
34809709	Association	MESH:D019636	12774
34809709	Association	177	4035
34809709	Association	MESH:D000544	4137
34809709	Association	MESH:D009422	4035
34809709	Negative_Correlation	MESH:D000077592	54103
34809709	Positive_Correlation	MESH:D015658	351
34809709	Negative_Correlation	MESH:D000077592	12774
34809709	Association	12774	4137
34809709	Association	MESH:D014766	1234

